| abstract |
IT REFERS TO A COMPOUND OF FORMULA I; R1 AND R2 ARE H, FLOWER OR ALKYL; R3 IS ARYL OR HETEROARIL, PREFERABLY A GROUP a; Y IS O, S, NR9; R4 ES H, ALKYL, CO-ALKYL, CONH-ALKYL, COO-ALKYL, SO2-ALKYL, C (NCN) NH-ALKYL, C (NNO2) NH-ALKYL, C (NH) NH-ALKYL, C (NH) NHCO-ALKYL, C (NOR6) NH-ALKYL, AMONG OTHERS; R5 IS H OR ALKYL; R6 IS H, ALKYL, CYCLOALKYL, ARYL, CYCLOALKYLALKYL, AMONG OTHERS; m IS 0-2; n IS 1-3; R7 AND R8 ARE H, ALKYL, CYCLOALKYL, AMONG OTHERS; R9 IS H, ALKYL, CYCLOALKYL, ARYL, AMONG OTHERS. PREFERRED COMPOUNDS ARE N- [5 - [[(5-ETIL-2-OXAZOLYL) METHYL] THIO] -2-THIAZOLYL] ACETAMIDE, N- [5 - [[(5-ETIL-2-OXAZOLYL) METHYL] THIO] -2-TIAZOLIL] BENZAMIDE, AMONG OTHERS. IT ALSO REFERS TO A COMPOSITION WHICH ALSO INCLUDES AN ANTI-CANCER AGENT. COMPOUND I IS A CYCLONE DEPENDENT ENZYME KINASE INHIBITOR AND MAY BE USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES, LIKE CANCER, INFLAMMATION, INFLAMMATORY DISEASE OF THE INTESTINE, INFECTIONS, VIRAL, INFECTIONS, INFECTIONS FUNGI, NEURODEGENERATIVE DISEASES |